Vienna Insurance Group’s C4 Therapeutics CCCC Stock Holding History

Vienna Insurance Group’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$224K	Hold	85,000	–	–	0.09%	28
2025 Q4	$162K	Hold	85,000	–	–	0.08%	26
2025 Q3	$189K	Hold	85,000	–	–	0.11%	26
2025 Q2	$122K	Hold	85,000	–	–	0.08%	88
2025 Q1	$136K	Hold	85,000	–	–	0.07%	93
2024 Q4	$306K	Hold	85,000	–	–	0.18%	85
2024 Q3	$485K	Hold	85,000	–	–	0.21%	91
2024 Q2	$393K	Hold	85,000	–	–	0.15%	94
2024 Q1	$694K	Hold	85,000	–	–	0.27%	95
2023 Q4	$480K	Hold	85,000	–	–	0.22%	91
2023 Q3	$158K	Hold	85,000	–	–	0.07%	91
2023 Q2	$234K	Hold	85,000	–	–	0.11%	88
2023 Q1	$267K	Hold	85,000	–	–	0.16%	88
2022 Q4	$502K	Hold	85,000	–	–	0.39%	33
2022 Q3	$745K	Hold	85,000	–	–	0.53%	35
2022 Q2	$641K	Hold	85,000	–	–	0.43%	36
2022 Q1	$2.06M	Buy	85,000 +40,000	+89%	+$971K	1.16%	32
2021 Q4	$1.45M	Buy	+45,000	New	+$1.78M	0.99%	28

Other funds holding CCCC

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vienna Insurance Group's CCCC Position: Q1 2026 in Review

Vienna Insurance Group held its C4 Therapeutics (CCCC) position steady in Q1 2026 at 85,000 shares worth $224K. The position accounts for 0.09% of the portfolio, ranked #28.

Vienna Insurance Group first reported a position in CCCC in Q4 2021 and has held it in 18 quarters since. The position peaked at $2.06M in Q1 2022. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

Vienna Insurance Group held 85,000 shares of C4 Therapeutics worth $224K as of Q1 2026.
Vienna Insurance Group left its C4 Therapeutics share count unchanged in Q1 2026.
C4 Therapeutics made up 0.09% of Vienna Insurance Group's portfolio in Q1 2026, its #28 holding.
Vienna Insurance Group first reported a position in C4 Therapeutics in Q4 2021 and has held it in 18 quarters since.
Vienna Insurance Group's C4 Therapeutics position peaked at $2.06M in Q1 2022.
123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Vienna Insurance Group's 13F filing for Q1 2026, filed 5 May 2026.